Exh. 10.9-Edinburg Amended Note Purchase Agreement
THIS AMENDED NOTE PURCHASE AGREMENT REPLACES IN ITS ENTIRETY THAT CERTAIN NOTE
PURCHASE AGREEMENT DATED MARCH 31, 2006 BETWEEN MEDICAL MEDIA TELEVISION, INC.
AND XXXXXX X. EDINBURG.
NOTE PURCHASE AGREEMENT
This NOTE PURCHASE AGREEMENT (this "Agreement"), dated as of March 31,
2006, is entered into by and among Medical Media Television, Inc., a Florida
corporation (the "Company"), and Xxxxxx X. Edinburg, an individual residing in
Colorado (the "Purchaser"), for the issuance and sale to the Purchaser of the
Note (as defined below) of the Company, in the manner, and upon the terms,
provisions and conditions set forth in this Agreement.
WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Company shall issue and sell to the Purchaser
and the Purchaser shall purchase the Note;
WHEREAS, such issuance and sale will be made in reliance upon the
provisions of Section 4(2) and/or Rule 506 of Regulation D ("Regulation D") of
the United States Securities Act of 1933, as amended, and regulations
promulgated thereunder (the "Securities Act"), or upon such other exemption from
the registration requirements of the Securities Act as may be available with
respect to the purchase of the Note to be made hereunder.
NOW, THEREFORE, in consideration of the representations, warranties and
agreements contained herein and other good and valuable consideration, the
receipt and legal adequacy of which is hereby acknowledged by the parties, the
Company and the Purchaser hereby agree as follows:
1. Purchase and Sale of Note.
(a) Terms of Note: Upon the following terms and subject to the
conditions contained herein, the Company shall issue and sell to the Purchaser,
and the Purchaser shall purchase from the Company, a convertible promissory note
in the aggregate principal amount of $10,000 (the "Purchase Price"), in
substantially the form attached hereto as Exhibit A (the "Note"). The
outstanding principal amount of the Note, plus any accrued but unpaid interest
thereon, shall be due and payable in cash on the Maturity Date (as defined in
the Note); provided, however, the Purchaser shall have the sole option to
convert on the Maturity Date the outstanding principal amount of the Note plus
any accrued but unpaid interest into such number of shares of Common Stock of
the Company, par value $.0005 per share (the "Common Stock"), at a Conversion
Price selected by the Holder. For purposes of this Note, "Conversion Price"
shall mean either (i) an amount equal to forty cents ($0.40), or (ii) an amount
equal to a twenty percent (20%) discount to the then-current market price based
on the average closing price for the twenty (20) days immediately preceding the
conversion, with the exception that the Conversion Price shall not be lower than
$0.166.
The Note shall bear interest at a rate of twenty percent (20%) per
annum, compounded semi-annually. Interest shall be paid at the end of each
quarter in either (i) shares of Series C Zero Coupon Preferred Stock of the
Company valued at $1.00 per share, or (ii) cash, at Investor's option, with the
first interest payment being on June 30, 2006. The Series C Zero Coupon
Preferred Stock shall be convertible into shares of the Company's Common Stock
on the Maturity date at a ten percent (10%) discount to the then-current market
price based on the average closing price for the twenty (20) days immediately
preceding the conversion. The Series C Zero Coupon Preferred Stock is
subordinate to Series A Zero Coupon Preferred Stock and Series B Zero Coupon
Preferred Stock. Investor shall make his election as to receipt of interest in
cash or in Series C Zero Coupon Preferred Stock by written notice to the Company
at least five (5) business days before the interest payment due date (the
"Interest Notice Date"). If no such notice is given by Investor by such Interest
Notice Date, the Company shall pay the interest in cash.
With the consent of both the Company and the Investor, the Note may be
extended for an additional twelve (12) months, with the terms of the interest
payments remaining the same as above.
(b) Issuance of Warrants: The Investor will be issued 25,000
warrants to purchase Common Stock of the Company (the "Warrants"). The Warrants
shall have a term of five (5) years and shall have an exercise price equal to
$0.75 per share (the "Exercise Price").
(c) In consideration of and in express reliance upon the
representations, warranties, covenants, terms and conditions of this Agreement,
the Company agrees to issue and sell to the Purchaser and the Purchaser agrees
to purchase the Note. The closing under this Agreement (the "Closing") shall
take place at the offices of Medical Media Television, Inc., 0000 Xxxxxxxx Xxxx,
Xxxxx X, Xxxxx, Xxxxxxx 00000 upon the satisfaction of each of the conditions
set forth in Sections 4 and 5 hereof (the "Closing Date").
(d) The Company has authorized and reserved and covenants to
continue to reserve, free of preemptive rights and other similar contractual
rights of stockholders, a number of authorized but unissued shares of Common
Stock to effect the conversion of the Note. Any shares of Common Stock issuable
by the Company upon conversion of the Note are herein referred to as the
"Conversion Shares". The Note and the Conversion Shares are sometimes
collectively referred to herein as the "Securities".
(e) The Investor is aware that the Company filed a
Registration Statement on Form SB-2 which was approved by the Securities &
Exchange Commission on March 1, 2006 and that no unspecified shares of Common
Stock to cover the conversion of this Note or Warrants were registered
thereunder. The Company therefore grants the Investor standard piggy-back
registration rights.
2. Representations, Warranties and Covenants of the Purchaser. The
Purchaser hereby makes the following representations and warranties to the
Company, and covenants for the benefit of the Company:
(a) If the Purchaser is an entity, the Purchaser is a
corporation, limited liability company or partnership duly incorporated or
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization.
(b) This Agreement has been duly authorized, validly executed
and delivered by the Purchaser and is a valid and binding agreement and
obligation of the Purchaser enforceable against the Purchaser in accordance with
its terms, subject to limitations on enforcement by general principles of equity
and by bankruptcy or other laws affecting the enforcement of creditors' rights
generally, and the Purchaser has full power and authority to execute and deliver
this Agreement and the other agreements and documents contemplated hereby and to
perform its obligations hereunder and thereunder.
(c) The Purchaser understands that no Federal, state, local or
foreign governmental body or regulatory authority has made any finding or
determination relating to the fairness of an investment in any of the Securities
and that no Federal, state, local or foreign governmental body or regulatory
authority has recommended or endorsed, or will recommend or endorse, any
investment in any of the Securities. The Purchaser, in making the decision to
purchase the Securities, has relied upon independent investigation made by it
and has not relied on any information or representations made by third parties.
2
(d) The Purchaser understands that the Securities are being
offered and sold to it in reliance on specific provisions of Federal and state
securities laws and that the Company is relying upon the truth and accuracy of
the representations, warranties, agreements, acknowledgments and understandings
of the Purchaser set forth herein for purposes of qualifying for exemptions from
registration under the Securities Act, and applicable state securities laws.
(e) The Purchaser is an "accredited investor" as defined under
Rule 501 of Regulation D promulgated under the Securities Act.
(f) The Purchaser is and will be acquiring the Securities for
its own account, and not with a view to any resale or distribution of the Note
in whole or in part, in violation of the Securities Act or any applicable
securities laws.
(g) The offer and sale of the Securities is intended to be
exempt from registration under the Securities Act, by virtue of Section 4(2)
and/or Rule 506 of Regulation D promulgated under the Securities Act. The
Purchaser understands that the Securities purchased hereunder have not been, and
may never be, registered under the Securities Act and that none of the
Securities can be sold or transferred unless they are first registered under the
Securities Act and such state and other securities laws as may be applicable or
in the opinion of counsel for the Company an exemption from registration under
the Securities Act is available (and then the Securities may be sold or
transferred only in compliance with such exemption and all applicable state and
other securities laws).
3. Representations, Warranties and Covenants of the Company. The
Company represents and warrants to the Purchaser, and covenants for the benefit
of the Purchaser, as follows:
(a) The Company has been duly incorporated and is validly
existing and in good standing under the laws of the State of Florida, with full
corporate power and authority to own, lease and operate its properties and to
conduct its business as currently conducted, and is duly registered and
qualified to conduct its business and is in good standing in each jurisdiction
or place where the nature of its properties or the conduct of its business
requires such registration or qualification, except where the failure to
register or qualify would not have a Material Adverse Effect. For purposes of
this Agreement, "Material Adverse Effect" shall mean any effect on the business,
results of operations, prospects, assets or financial condition of the Company
that is material and adverse to the Company and its subsidiaries and affiliates
and/or any condition, circumstance, or situation that would prohibit or
otherwise materially interfere with the ability of the Company from entering
into and performing any of its obligations under this Agreement or the Note in
any material respect.
(b) The Note has been duly authorized by all necessary
corporate action and, when paid for or issued in accordance with the terms
hereof, the Note shall be validly issued and outstanding, free and clear of all
liens, encumbrances and rights of refusal of any kind. When the Conversion
Shares are issued and paid for in accordance with the terms of this Agreement
and as set forth in the Note, such shares will be duly authorized by all
necessary corporate action and validly issued and outstanding, fully paid and
nonassessable, free and clear of all liens, encumbrances and rights of refusal
of any kind and the holders shall be entitled to all rights accorded to a holder
of Common Stock.
(c) The Note and this Agreement (the "Transaction Documents")
have been duly authorized, validly executed and delivered on behalf of the
Company and is a valid and binding agreement and obligation of the Company
enforceable against the Company in accordance with its terms, subject to
limitations on enforcement by general principles of equity and by bankruptcy or
other laws affecting the enforcement of creditors' rights generally, and the
Company has full power and authority to execute and deliver the Transaction
Documents and the other agreements and documents contemplated hereby and to
perform its obligations hereunder and thereunder.
3
(d) The execution and delivery of the Transaction Documents
and the consummation of the transactions contemplated by this Agreement by the
Company, will not (i) conflict with or result in a breach of or a default under
any of the terms or provisions of, (A) the Company's certificate of
incorporation or by-laws, or (B) of any material provision of any indenture,
mortgage, deed of trust or other material agreement or instrument to which the
Company is a party or by which it or any of its material properties or assets is
bound, (ii) result in a violation of any material provision of any law, statute,
rule, regulation, or any existing applicable decree, judgment or order by any
court, Federal or state regulatory body, administrative agency, or other
governmental body having jurisdiction over the Company, or any of its material
properties or assets or (iii) result in the creation or imposition of any
material lien, charge or encumbrance upon any material property or assets of the
Company or any of its subsidiaries pursuant to the terms of any agreement or
instrument to which any of them is a party or by which any of them may be bound
or to which any of their property or any of them is subject except in the case
of clauses (i)(B) or (iii) for any such conflicts, breaches, or defaults or any
liens, charges, or encumbrances which would not have a Material Adverse Effect.
(e) The sale and issuance of the Securities in accordance with
the terms of and in reliance on the accuracy of the Purchaser's representations
and warranties set forth in this Agreement will be exempt from the registration
requirements of the Securities Act.
(f) No consent, approval or authorization of or designation,
declaration or filing with any governmental authority on the part of the Company
is required in connection with the valid execution and delivery of this
Agreement or the offer, sale or issuance of the Securities or the consummation
of any other transaction contemplated by this Agreement.
(g) There is no action, suit, claim, investigation or
proceeding pending or, to the knowledge of the Company, threatened against the
Company which questions the validity of the Transaction Documents or the
transactions contemplated thereby or any action taken or to be taken pursuant
thereto. There is no action, suit, claim, investigation or proceeding pending
or, to the knowledge of the Company, threatened, against or involving the
Company or any subsidiary, or any of their respective properties or assets
which, if adversely determined, is reasonably likely to result in a Material
Adverse Effect.
(h) The Company has complied and will comply with all
applicable federal and state securities laws in connection with the offer,
issuance and sale of the Note hereunder. Neither the Company nor anyone acting
on its behalf, directly or indirectly, has or will sell, offer to sell or
solicit offers to buy the Note, or similar securities to, or solicit offers with
respect thereto from, or enter into any preliminary conversations or
negotiations relating thereto with, any person, or has taken or will take any
action so as to bring the issuance and sale of the Note under the registration
provisions of the Securities Act and any other applicable federal and state
securities laws. Neither the Company nor any of its affiliates, nor any person
acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D under the Securities
Act) in connection with the Note.
(i) To the Company's knowledge, neither this Agreement, nor
the Schedules hereto contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements made herein or
therein, in the light of the circumstances under which they were made herein or
therein, not misleading.
4
(j) The authorized capital stock of the Company and the shares
thereof issued and outstanding as of March 30, 2006 are set forth on Schedule
3(j) attached hereto. All of the outstanding shares of the Common Stock have
been duly and validly authorized, and are fully paid and non-assessable. Except
as set forth in this Agreement or on Schedule 3(j) attached hereto, as of the
date hereof, no shares of the Common Stock are entitled to preemptive rights and
there are no registration rights or outstanding options, warrants, scrip, rights
to subscribe to, call or commitments of any character whatsoever relating to, or
securities or rights convertible into, any shares of capital stock of the
Company. As of the date hereof, except for as set forth on Schedule 3(j), the
Company is not a party to any agreement granting registration rights to any
person with respect to any of its equity or debt securities. The Company is not
a party to, and its executive officers have no knowledge of, any agreement
restricting the voting or transfer of any shares of the capital stock of the
Company. The offer and sale of all capital stock, convertible securities,
rights, warrants, or options of the Company issued prior to the Closing complied
with all applicable federal and state securities laws, or no stockholder has a
right of rescission or damages with respect thereto which is reasonably likely
to have a Material Adverse Effect. The Company has furnished or made available
to the Purchaser true and correct copies of the Company's Certificate of
Incorporation as in effect on the date hereof (the "Certificate"), and the
Company's Bylaws as in effect on the date hereof (the "Bylaws").
(k) So long as the Note remains outstanding, the Company shall
take all action necessary to at all times have authorized, and reserved for the
purpose of issuance, a sufficient number of shares of Common Stock to effect the
conversion of the Note.
(l) The Company has complied and will comply with all
applicable federal and state securities laws in connection with the offer,
issuance and sale of the Note and the Conversion Shares hereunder. Neither the
Company nor anyone acting on its behalf, directly or indirectly, has or will
sell, offer to sell or solicit offers to buy any of the Securities, or similar
securities to, or solicit offers with respect thereto from, or enter into any
preliminary conversations or negotiations relating thereto with, any person, or
has taken or will take any action so as to bring the issuance and sale of any of
the Securities under the registration provisions of the Securities Act and
applicable state securities laws. Neither the Company nor any of its affiliates,
nor any person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D under
the Securities Act) in connection with the offer or sale of any of the
Securities.
4. Conditions Precedent to the Obligation of the Company to Sell the
Note. The obligation hereunder of the Company to issue and sell the Note to the
Purchaser is subject to the satisfaction or waiver, at or before the Closing
Date, of each of the conditions set forth below. These conditions are for the
Company's sole benefit and may be waived by the Company at any time in its sole
discretion.
(a) The Purchaser shall have executed and delivered this
Agreement.
(b) The Purchaser shall have performed, satisfied and complied
in all material respects with all covenants, agreements and conditions required
to be performed, satisfied or complied with by the Purchaser at or prior to the
Closing Date.
(c) The representations and warranties of the Purchaser shall
be true and correct in all material respects as of the date when made and as of
the Closing Date as though made at that time, except for representations and
warranties that are expressly made as of a particular date, which shall be true
and correct in all material respects as of such date.
5
(d) At the Closing Date, the Purchaser shall have delivered to
the Company immediately available funds as payment in full of the Purchase Price
for the Note.
5. Conditions Precedent to the Obligation of the Purchaser to Purchase
the Note. The obligation hereunder of the Purchaser to acquire and pay for the
Note is subject to the satisfaction or waiver, at or before the Closing Date, of
each of the conditions set forth below. These conditions are for the Purchaser's
sole benefit and may be waived by the Purchaser at any time in its sole
discretion.
(a) The Company shall have executed and delivered the Note,
this Agreement and any other Transaction Document.
(b) The Company shall have performed, satisfied and complied
in all material respects with all covenants, agreements and conditions required
by the Transaction Documents to be performed, satisfied or complied with by the
Company at or prior to the Closing Date.
(c) Each of the representations and warranties of the Company
shall be true and correct in all material respects as of the date when made and
as of the Closing Date as though made at that time (except for representations
and warranties that speak as of a particular date), which shall be true and
correct in all material respects as of such date.
(d) No statute, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by any
court or governmental authority of competent jurisdiction which prohibits the
consummation of any of the transactions contemplated by this Agreement at or
prior to the Closing Date.
(e) As of the Closing Date, no action, suit or proceeding
before or by any court or governmental agency or body, domestic or foreign,
shall be pending against or affecting the Company, or any of its properties,
which questions the validity of the Agreement, the Note, or the transactions
contemplated thereby or any action taken or to be take pursuant thereto. As of
the Closing Date, no action, suit, claim or proceeding before or by any court or
governmental agency or body, domestic or foreign, shall be pending against or
affecting the Company, or any of its properties, which, if adversely determined,
is reasonably likely to result in a Material Adverse Effect.
(f) No Material Adverse Effect shall have occurred at or
before the Closing Date.
(g) The Company shall have delivered on the Closing Date to
the Purchaser a secretary's certificate, dated as of the Closing Date, as to (i)
the resolutions of the board of directors of the Company authorizing the
transactions contemplated by this Agreement, (ii) the Certificate, (iii) the
Bylaws, each as in effect at the Closing, and (iv) the authority and incumbency
of the officers of the Company executing this Agreement and the Note.
(h) The Purchaser shall have received a legal opinion in
substantially the form annexed hereto as Exhibit B as of the Closing Date.
6
6. Legend. Each Note and certificate representing the Conversion Shares
shall be stamped or otherwise imprinted with a legend substantially in the
following form (in addition to any legend required by applicable state
securities or "blue sky" laws):
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE
"SECURITIES") HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY STATE
SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND
UNDER APPLICABLE STATE SECURITIES LAWS OR MEDICAL MEDIA
TELEVISION, INC. SHALL HAVE RECEIVED AN OPINION OF COUNSEL
THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS
IS NOT REQUIRED."
The Company agrees to reissue the Note and certificates representing the
Conversion Shares, without the legend set forth above if at such time, prior to
making any transfer of any such Securities, such holder thereof shall give
written notice to the Company describing the manner and terms of such transfer
and removal as the Company may reasonably request. Such proposed transfer will
not be effected until: (a) the Company has notified such holder that either (i)
in the opinion of its counsel, the registration of the Note or Conversion Shares
under the Securities Act is not required in connection with such proposed
transfer; or (ii) a registration statement under the Securities Act covering
such proposed disposition has been filed by the Company with the Securities and
Exchange Commission and has become effective under the Securities Act; and (b)
the Company has notified such holder that either: (i) in the opinion of its
counsel, the registration or qualification under the securities or "blue sky"
laws of any state is not required in connection with such proposed disposition,
or (ii) compliance with applicable state securities or "blue sky" laws has been
effected. The Company will use its best efforts to respond to any such notice
from a holder within five (5) days. In the case of any proposed transfer under
this Section 6, the Company will use reasonable efforts to comply with any such
applicable state securities or "blue sky" laws, but shall in no event be
required, in connection therewith, to qualify to do business in any state where
it is not then qualified or to take any action that would subject it to tax or
to the general service of process in any state where it is not then subject. The
restrictions on transfer contained in this Section 6 shall be in addition to,
and not by way of limitation of, any other restrictions on transfer contained in
any other section of this Agreement.
7. Indemnification.
(a) The Company hereby agrees to indemnify and hold harmless
the Purchaser and its officers, directors, shareholders, employees, agents and
attorneys against any and all losses, claims, damages, liabilities and
reasonable expenses (collectively "Claims") incurred by each such person in
connection with defending or investigating any such Claims, whether or not
resulting in any liability to such person, to which any such indemnified party
may become subject, insofar as such Claims arise out of or are based upon any
breach of any representation or warranty or agreement made by the Company in
this Agreement.
(b) The Purchaser hereby agrees to indemnify and hold harmless
the Company and its officers, directors, shareholders, employees, agents and
attorneys against any and all losses, claims, damages, liabilities and expenses
incurred by each such person in connection with defending or investigating any
such claims or liabilities, whether or not resulting in any liability to such
person, to which any such indemnified party may become subject under the
Securities Act, or under any other statute, at common law or otherwise, insofar
as such Claims arise out of or are based upon (i) any untrue statement or
alleged untrue statement of a material fact made by the Purchaser, (ii) any
omission or alleged omission of a material fact with respect to the Purchaser or
(iii) any breach of any representation, warranty or agreement made by the
Purchaser in this Agreement.
7
8. Governing Law; Consent to Jurisdiction. This Agreement shall be
governed by and interpreted in accordance with the laws of the State of Florida
without giving effect to the rules governing the conflicts of laws. Each of the
parties consents to the exclusive jurisdiction of the Federal courts whose
districts encompass any part of the County of Hillsborough located in the City
of Tampa in connection with any dispute arising under this Agreement and hereby
waives, to the maximum extent permitted by law, any objection, including any
objection based on forum non conveniens, to the bringing of any such proceeding
in such jurisdictions. Each party waives its right to a trial by jury. Each
party to this Agreement irrevocably consents to the service of process in any
such proceeding by the mailing of copies thereof by registered or certified
mail, postage prepaid, to such party at its address set forth herein. Nothing
herein shall affect the right of any party to serve process in any other manner
permitted by law.
9. Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand delivery, express overnight
courier, registered first class mail, or telecopier (provided that any notice
sent by telecopier shall be confirmed by other means pursuant to this Section
10), initially to the address set forth below, and thereafter at such other
address, notice of which is given in accordance with the provisions of this
Section.
(a) if to the Company:
Medical Media Television, Inc.
0000 Xxxxxxxx Xxxx, Xxxxx X
Xxxxx, Xxxxxxx 00000
Attention: Xxxxxx X. Xxxxx, President/Chief Executive
Officer
Tel. No.: (000) 000-0000
Fax No.: (000) 000-0000
with a copy to:
Xxxx Xxxx Xxxxxxx Xxxxxx & Xxxx, P.A.
000 X. Xxxxxxxx Xx.
Xxxxx, XX 00000
Attn: Xxxx X. Xxxxxxxx
Tel. No.: (000) 000-0000
Fax No.: (000) 000-0000
(b) if to the Purchaser:
Xxxxxx X. Edinburg
XX Xxx 0000
Xxxxxxx, XX 00000
Tel. No.: (000) 000-0000
Fax No.: (000) 000-0000
All such notices and communications shall be deemed to have been duly given:
when delivered by hand, if personally delivered; when receipt is acknowledged,
if telecopied; or when actually received or refused if sent by other means.
8
10. Assignment. Neither party may assign, sell, or transfer to any
third person the rights of such party hereunder; provided, however, that
Purchaser may assign his rights hereunder to an entity wholly owned and
controlled by Purchaser.
11. Entire Agreement. This Agreement, the Note and any other
Transaction Document constitute the entire understanding and agreement of the
parties with respect to the subject matter hereof and supersedes all prior
and/or contemporaneous oral or written proposals or agreements relating thereto
all of which are merged herein. This Agreement may not be amended or any
provision hereof waived in whole or in part, except by a written amendment
signed by both of the parties.
12. Counterparts. This Agreement may be executed by facsimile signature
and in counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
IN WITNESS WHEREOF, in accordance with amendment provisions contained
herein, this Amended Note Purchase Agreement was duly executed on the 28th day
of June, 2006 with an effective date as of the date first written above.
MEDICAL MEDIA TELEVISION, INC.
By: /s/ Xxxxxx X. Xxxxx
-----------------------------------------------
Name: Xxxxxx X. Xxxxx
Title: President and Chief Executive Officer
PURCHASER:
By: /s/ Xxxxxx X. Edinburg
-----------------------------------------------
Name: Xxxxxx X. Edinburg
9
EXHIBIT A
---------
FORM OF NOTE
10
EXHIBIT B
---------
FORM OF OPINION
1. The Company is a corporation duly incorporated, validly existing and
in good standing under the laws of the State of Florida and has the requisite
corporate power to own, lease and operate its properties and assets, and to
carry on its business as presently conducted. The Company is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.
2. The Company has the requisite corporate power and authority to enter
into and perform its obligations under the Transaction Documents and to issue
the Securities. The execution, delivery and performance of the Transaction
Documents by the Company and the consummation by it of the transactions
contemplated thereby have been duly and validly authorized by all necessary
corporate action and no further consent or authorization of the Company or its
Board of Directors is required. The Transaction Documents have been duly
executed and delivered, and the Note has been duly executed, issued and
delivered by the Company and each Transaction Document constitutes a legal,
valid and binding obligation of the Company enforceable against the Company in
accordance with its respective terms. The Conversion Shares are not subject to
any preemptive rights under the Certificate of Incorporation or the Bylaws.
3. The Note has been duly authorized and, when delivered against
payment in full as provided in the Purchase Agreement, will be validly issued.
The Conversion Shares have been duly authorized for issuance, and when delivered
upon conversion or against payment in full as provided in the Note, will be
validly issued, fully paid and nonassessable.
4. The execution, delivery and performance of and compliance with the
terms of the Transaction Documents and the issuance of the Securities do not (a)
violate any provision of the Certificate of Incorporation or Bylaws, (b) to our
knowledge, after due inquiry, conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any material agreement, mortgage, deed of trust, indenture,
note, bond, license, lease agreement, instrument or obligation to which the
Company is a party and which is known to us, (c) to our knowledge, after due
inquiry, create or impose a lien, charge or encumbrance on any property of the
Company under any agreement or any commitment known to us to which the Company
is a party or by which the Company is bound or by which any of its respective
properties or assets are bound, or (d) result in a violation of any Federal,
state, local or foreign statute, rule, regulation, order, judgment, injunction
or decree (including Federal and state securities laws and regulations)
applicable to the Company or by which any property or asset of the Company is
bound or affected, except, in all cases other than violations pursuant to
clauses (a) and (d) above, for such conflicts, default, terminations,
amendments, acceleration, cancellations and violations as would not,
individually or in the aggregate, have a Material Adverse Effect.
5. No consent, approval or authorization of or designation, declaration
or filing with any governmental authority on the part of the Company is required
under Federal, state or local law, rule or regulation in connection with the
valid execution, delivery and performance of the Transaction Documents, or the
offer, sale or issuance of the Note or the Conversion Shares.
11
6. To our knowledge, there is no action, suit, claim, investigation or
proceeding pending or threatened against the Company which questions the
validity of the Purchase Agreement or the transactions contemplated thereby or
any action taken or to be taken pursuant thereto. There is no action, suit,
claim, investigation or proceeding pending, or to our knowledge, threatened,
against or involving the Company or any of its properties or assets and which,
if adversely determined, is reasonably likely to result in a Material Adverse
Effect. There are no outstanding orders, judgments, injunctions, awards or
decrees of any court, arbitrator or governmental or regulatory body against the
Company or any officers or directors of the Company in their capacities as such.
7. Conditioned on the accuracy of the Purchaser's representations and
warranties contained in the Purchase Agreement, the offer, issuance and sale of
the Note and the offer, issuance and sale of the Conversion Shares pursuant to
the Purchase Agreement and the Note, as applicable, are exempt from the
registration requirements of the Securities Act of 1933, as amended.
12
SCHEDULE 3j
-----------
Medical Media Television, Inc. Capital Stock:
Common Stock: Authorized Shares: 100,000,000 shares
Outstanding Shares: 21,117,136 shares
Par Value: $.0005
Preferred Stock: Total Authorized Shares: 25,000,000 shares
Total Outstanding Shares: 4,303,959 shares
Par Value: Zero
Series A Zero Coupon Preferred Stock: Authorized Shares: 1,682,044 shares
Outstanding Shares: 1,682,044 shares
Series B Zero Coupon Preferred Stock: Authorized Shares: 2,612,329 shares
Outstanding Shares: 2,612,329 shares
Series C Zero Coupon Preferred Stock: Authorized Shares: 400,000 shares
Outstanding Shares: 8,627 shares
OUTSTANDING OPTIONS, WARRANTS, AND OTHER RIGHTS TO ACQUIRE SHARES OF
MEDICAL MEDIA TELEVISION, INC.
Outstanding stock options to purchase 66,667 shares of common stock of MMTV.
Outstanding warrants to purchase 13,779,235 shares of common stock of MMTV.
Outstanding Series A and Series B preferred shares which will convert into
16,093,989 shares of common stock of MMTV.
Outstanding Series C preferred shares which will convert into common shares at a
discount to market at time of conversion.
Outstanding convertible debentures which will convert into 9,721,655 shares of
common stock of MMTV. These convertible debentures may be repaid in cash at the
option of the Company.
The above calculations do not include any shares of Series C preferred stock
that may be issued for interest payments on existing convertible debt
instruments that will be converted into common shares at a discount to market at
time of conversion. It also does not include any common shares that may be
issued for interest payments on existing convertible debt instruments. Full
disclose of the above has been made in a registration statement on Form SB-2
which was declared effective by the SEC on March 1, 2006 and is available to
viewing at xxx.xxx.xxx.
13
